Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov;17(6):479-486.
doi: 10.2450/2019.0211-19. Epub 2019 Dec 11.

Factor VIII replacement is still the standard of care in haemophilia A

Louis Aledort  1 , Pier Mannuccio Mannucci  2 , Wolfgang Schramm  3 , Michael Tarantino  4
Affiliations
Review

Factor VIII replacement is still the standard of care in haemophilia A

Louis Aledort et al. Blood Transfus. 2019 Nov.

Abstract

Prophylactic factor VIII (FVIII) has dramatically improved haemophilia A treatment, preventing joint bleeding and halting the deterioration of joint status. FVIII products with an extended plasma half-life further improve patients' quality of life and increase therapeutic adherence. New licensed classes of non-replacement products include prophylactic emicizumab, which is administered subcutaneously up to every 4 weeks. However, this drug is not suitable for acute bleeding episodes or management of major surgery, and long-term data on the impact of emicizumab on joint health, FVIII inhibitor development and thrombotic risk are awaited. Prophylaxis with FVIII replacement remains the standard of care in haemophilia A, with the aim of achieving a level of haemostasis control that allows patients to meet their lifestyle goals.

PubMed Disclaimer

Conflict of interest statement

Disclosures of conflicts of interest

LA has participated in a Data Safety Monitoring Board for Octapharma and Takeda. He has also received honoraria from Bayer, Kedrion, and Takeda, and has acted as Chair for a scientific advisory committee for Kedrion. PMM sits on the scientific board for the Bayer Awards. He has also received honoraria for lectures at educational symposia from Bayer, Kedrion and Novo Nordisk. WS has participated in a Data Safety Monitoring Board for Biotest and received honoraria for lectures from Biotest, Novo Nordisk, Roche, Takeda and Bio&Bio. MT has been an advisor for Amgen, Genentech, Kedrion, Novo Nordisk, Octapharma and Takeda. He has received fees for lectures at symposia for Takeda. Research with Novo Nordisk and Takeda.

Comment in

  • "The times they are a-changin", ... or maybe not?
    Franchini M, Liumbruno GM. Franchini M, et al. Blood Transfus. 2019 Nov;17(6):401-402. doi: 10.2450/2019.0259-19. Epub 2019 Dec 11. Blood Transfus. 2019. PMID: 31846604 Free PMC article. No abstract available.

References

    1. Mannucci PM, Iacobelli M. Progress in the contemporary management of hemophilia: The new issue of patient aging. Eur J Intern Med. 2017;43:16–21. - PubMed
    1. Chen SL. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Am J Manag Care. 2016;22:s126–33. - PubMed
    1. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9:418–35. - PubMed
    1. Rocino A, Franchini M, Coppola A. treatment and prevention of bleeds in haemophilia patients with inhibitors to factor VIII/IX. J Clin Med. 2017;6:e46. - PMC - PubMed
    1. DiMichele DM, Hoots WK, Pipe SW, et al. International workshop on immune tolerance induction: consensus recommendations. Haemophilia. 2007;13:1–22. - PubMed